CASE REPORTS
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Olecranon bursitis in patients treated with sunitinib for renal cell carcinoma.

Sunitinib is a recently approved tyrosine-kinase inhibitor that targets the vascular endothelial growth factor receptors (VEGFR). We report two cases of patients with metastatic renal cell cancer who developed olecranon bursitis while receiving sunitinib. In both cases other causes of bursitis were excluded and the symptoms resolved after treatment with sunitinib was discontinued. Recurrence of symptoms during subsequent treatment cycles was also observed. This adverse event has not been previously reported for sunitinib and we believe it is directly attributable to the drug. This is an unexpected adverse event, given the mechanism of action of the drug. The pathophysiology of this event remains unexplained, although we describe some hypotheses.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app